FDA fast tracks AstraZeneca diabetes drug

Aug 27, 2019

One of AstraZeneca's top drugs, the diabetes med Farxiga, has been given fast track status by the U.S. Food and Drug Administration as a method to prevent heart and kidney failure in patients with chronic kidney disease.

Farxiga is approved in the U.S. to treat type-2 diabetes but earlier in the year, regulators declined to approve Farxiga as a supplement to insulin in adults with type-1 diabetes where insulin alone was not able to control blood sugar levels.

Farxiga will compete with Novo Nordisk’s Victoza and Eli Lilly and Boehringer Ingelheim’s Jardiance. 

Read the Reueters report